Transforming cancer treatment and advancing new therapies through empowered science.

Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to... 
Read more

NASDAQ | SGEN (Common Stock)


 0.89 (2.51%)

Market Cap$4,955,633,520

05/02/16  4:00 p.m. ET

Minimum 20 minute delay

Latest Investor Information

Press Releases

Seattle Genetics Reports First Quarter 2016 Financial Results 04/28/16

Read more

Seattle Genetics Highlights Data Supporting Antibody-Drug Conjugate and Novel Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 04/18/16

Read more


1st Quarter 2016 Financial Results 04/28/16 4:30 p.m. ETView event
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources